Daniel Leonard Shaw, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Transfer | 1 | 2024 | 761 | 0.580 |
Why?
|
| Legislation, Medical | 1 | 2015 | 100 | 0.520 |
Why?
|
| Medicare Part D | 1 | 2018 | 328 | 0.480 |
Why?
|
| Federal Government | 1 | 2015 | 260 | 0.480 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 1584 | 0.460 |
Why?
|
| Prescription Drugs | 2 | 2018 | 595 | 0.420 |
Why?
|
| Drug Approval | 1 | 2018 | 742 | 0.420 |
Why?
|
| Drug Discovery | 2 | 2017 | 1058 | 0.410 |
Why?
|
| Information Dissemination | 1 | 2015 | 1099 | 0.300 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1901 | 0.300 |
Why?
|
| Registries | 1 | 2015 | 8089 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 7913 | 0.180 |
Why?
|
| Orphan Drug Production | 1 | 2018 | 50 | 0.160 |
Why?
|
| Formularies as Topic | 1 | 2017 | 91 | 0.150 |
Why?
|
| Methylene Blue | 1 | 2017 | 155 | 0.150 |
Why?
|
| Atovaquone | 1 | 2016 | 58 | 0.140 |
Why?
|
| Hydroxamic Acids | 1 | 2019 | 494 | 0.140 |
Why?
|
| Lyases | 1 | 2015 | 41 | 0.130 |
Why?
|
| Security Measures | 1 | 2015 | 77 | 0.130 |
Why?
|
| Neisseria meningitidis | 1 | 2015 | 109 | 0.130 |
Why?
|
| Captopril | 1 | 2015 | 272 | 0.130 |
Why?
|
| Debridement | 1 | 2017 | 492 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2019 | 783 | 0.120 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 587 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 789 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 683 | 0.120 |
Why?
|
| Arthritis, Infectious | 1 | 2017 | 367 | 0.110 |
Why?
|
| Privacy | 1 | 2015 | 239 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2014 | 216 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 873 | 0.100 |
Why?
|
| Cell Survival | 2 | 2019 | 5882 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 538 | 0.100 |
Why?
|
| Drug Industry | 1 | 2017 | 746 | 0.090 |
Why?
|
| Pyrazines | 1 | 2014 | 1230 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1518 | 0.080 |
Why?
|
| Imidazoles | 1 | 2014 | 1206 | 0.080 |
Why?
|
| Echocardiography | 1 | 2019 | 5102 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 2376 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2019 | 459 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2019 | 5985 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1458 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 1848 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 3848 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3309 | 0.050 |
Why?
|
| United States | 3 | 2018 | 69872 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8428 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2015 | 2011 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 5853 | 0.040 |
Why?
|
| Medicare | 1 | 2017 | 6566 | 0.040 |
Why?
|
| Vital Signs | 1 | 2019 | 142 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25043 | 0.040 |
Why?
|
| Time Factors | 1 | 2018 | 40075 | 0.040 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.040 |
Why?
|
| Anilides | 1 | 2019 | 408 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 16689 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 2016 | 457 | 0.030 |
Why?
|
| Pyridines | 2 | 2019 | 2825 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2015 | 354 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 913 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 12208 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 2017 | 425 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 944 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13695 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2015 | 698 | 0.030 |
Why?
|
| Humans | 8 | 2024 | 744343 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 336 | 0.030 |
Why?
|
| Alkanesulfonic Acids | 1 | 2014 | 180 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 2014 | 452 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2014 | 720 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 3002 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3129 | 0.020 |
Why?
|
| Knee Joint | 1 | 2017 | 1680 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3023 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 3282 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3748 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8436 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 5456 | 0.020 |
Why?
|
| Proteins | 1 | 2019 | 6103 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2019 | 53288 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 3462 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
| Mice | 2 | 2019 | 81183 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3523 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2017 | 63114 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7659 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9727 | 0.010 |
Why?
|
| Middle Aged | 3 | 2019 | 213383 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18029 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23403 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12072 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 168757 | 0.010 |
Why?
|
| Male | 3 | 2019 | 350118 | 0.010 |
Why?
|
| Female | 3 | 2019 | 380194 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 163280 | 0.010 |
Why?
|
| Adult | 2 | 2019 | 214055 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 77449 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 56430 | 0.010 |
Why?
|